Skolnick P[au] - Search Results

Year	Number of Results
1968	2
1970	1
1973	1
1974	2
1975	6
1976	3
1977	3
1978	10
1979	13
1980	16
1981	19
1982	20
1983	13
1984	17
1985	20
1986	27
1987	28
1988	22
1989	20
1990	22
1991	13
1992	21
1993	19
1994	13
1995	15
1996	11
1997	7
1998	14
1999	6
2000	4
2001	9
2002	4
2003	6
2004	3
2005	1
2006	3
2007	4
2008	3
2009	3
2010	1
2011	5
2012	9
2013	3
2014	4
2015	7
2016	6
2017	2
2018	5
2019	5
2020	2
2021	2
2022	1

1

The Opioid Epidemic: Crisis and Solutions.

Skolnick P. Skolnick P. Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:143-159. doi: 10.1146/annurev-pharmtox-010617-052534. Epub 2017 Oct 2. Annu Rev Pharmacol Toxicol. 2018. PMID: 28968188 Review.

2

Glutamate-based antidepressants: preclinical psychopharmacology.

Pilc A, Wierońska JM, Skolnick P. Pilc A, et al. Among authors: skolnick p. Biol Psychiatry. 2013 Jun 15;73(12):1125-32. doi: 10.1016/j.biopsych.2013.01.021. Epub 2013 Feb 28. Biol Psychiatry. 2013. PMID: 23453290 Review.

3

Countermeasures for Preventing and Treating Opioid Overdose.

France CP, Ahern GP, Averick S, Disney A, Enright HA, Esmaeli-Azad B, Federico A, Gerak LR, Husbands SM, Kolber B, Lau EY, Lao V, Maguire DR, Malfatti MA, Martinez G, Mayer BP, Pravetoni M, Sahibzada N, Skolnick P, Snyder EY, Tomycz N, Valdez CA, Zapf J. France CP, et al. Among authors: skolnick p. Clin Pharmacol Ther. 2021 Mar;109(3):578-590. doi: 10.1002/cpt.2098. Epub 2020 Nov 29. Clin Pharmacol Ther. 2021. PMID: 33113208 Free PMC article. Review.

4

Biologic Approaches to Treat Substance-Use Disorders.

Skolnick P. Skolnick P. Trends Pharmacol Sci. 2015 Oct;36(10):628-635. doi: 10.1016/j.tips.2015.07.002. Trends Pharmacol Sci. 2015. PMID: 26435208 Free PMC article. Review.

5

Medication development in opioid addiction: Meaningful clinical end points.

Volkow ND, Woodcock J, Compton WM, Throckmorton DC, Skolnick P, Hertz S, Wargo EM. Volkow ND, et al. Among authors: skolnick p. Sci Transl Med. 2018 Mar 28;10(434):eaan2595. doi: 10.1126/scitranslmed.aan2595. Sci Transl Med. 2018. PMID: 29593105 Review.

6

The development of glutamate-based antidepressants is taking longer than expected.

Garay R, Zarate CA Jr, Cavero I, Kim YK, Charpeaud T, Skolnick P. Garay R, et al. Among authors: skolnick p. Drug Discov Today. 2018 Oct;23(10):1689-1692. doi: 10.1016/j.drudis.2018.02.006. Epub 2018 Mar 1. Drug Discov Today. 2018. PMID: 29501913 Free PMC article. No abstract available.

7

Glutamate-based antidepressants: 20 years on.

Skolnick P, Popik P, Trullas R. Skolnick P, et al. Trends Pharmacol Sci. 2009 Nov;30(11):563-9. doi: 10.1016/j.tips.2009.09.002. Trends Pharmacol Sci. 2009. PMID: 19837463 Review.

8

Anxioselective anxiolytics: on a quest for the Holy Grail.

Skolnick P. Skolnick P. Trends Pharmacol Sci. 2012 Nov;33(11):611-20. doi: 10.1016/j.tips.2012.08.003. Epub 2012 Sep 14. Trends Pharmacol Sci. 2012. PMID: 22981367 Free PMC article. Review.

9

Triple reuptake inhibitors ("broad spectrum" antidepressants).

Skolnick P, Basile AS. Skolnick P, et al. CNS Neurol Disord Drug Targets. 2007 Apr;6(2):141-9. doi: 10.2174/187152707780363285. CNS Neurol Disord Drug Targets. 2007. PMID: 17430151 Review.

10

Be positive about negatives-recommendations for the publication of negative (or null) results.

Bespalov A, Steckler T, Skolnick P. Bespalov A, et al. Among authors: skolnick p. Eur Neuropsychopharmacol. 2019 Dec;29(12):1312-1320. doi: 10.1016/j.euroneuro.2019.10.007. Epub 2019 Nov 18. Eur Neuropsychopharmacol. 2019. PMID: 31753777 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results